Bptf determines oncogenic addiction in aggressive B-cell lymphomas.

Area of Science:

• Oncology
• Molecular Biology
• Epigenetics

Background:

• Chromatin remodeling factors drive cancer gene expression and are therapeutic targets.
• Bromodomain PhD Transcription Factor (BPTF), a NURF subunit, influences oncogenic c-MYC activity in pancreatic cancer.

Purpose of the Study:

• To investigate the role of BPTF in c-MYC-driven B-cell lymphomagenesis using a transgenic mouse model.
• To evaluate BPTF as a potential therapeutic target in B-cell lymphomas.

Main Methods:

• Utilized the Eμ-Myc transgenic mouse model for aggressive B-cell lymphoma.
• Analyzed B-cell differentiation, lymphomagenesis progression, and molecular alterations in Bptf heterozygous backgrounds.
• Correlated BPTF, c-MYC, and NF-κB pathway activity in both mouse models and human B-cell lymphoma samples.

Main Results:

• BPTF is essential for normal B-cell differentiation; haploinsufficiency delays lymphomagenesis in Eμ-Myc mice.
• Tumors in Bptf heterozygous mice showed reduced c-MYC activity and increased NF-κB pathway activation, mirroring human DLBCL.
• Significant correlation between BPTF and c-MYC, and anti-correlation between BPTF and NF-κB were observed in human lymphoma samples.

Conclusions:

• BPTF plays a significant role in B-cell lymphomagenesis and is a viable therapeutic target.
• Inhibition of BPTF leads to altered oncogenic dependencies in B-cell lymphomas, offering new therapeutic avenues.